跳至主要内容
临床试验/JPRN-jRCT1080223870
JPRN-jRCT1080223870招募中Unknown

Intuniv Tablets drug use-results survey (Surveillance regarding pediatric use)

SHIONOGI & CO., LTD.0 个研究点目标入组 75 人开始时间: 2018年4月16日最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
入组人数
75

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
>= 6age old 至 <= 18age old(—)
性别
All

入选标准

  • Patients with attention deficit/hyperactivity disorder (AD/HD) who fulfill the following criteria will be included in the surveillance.
  • Inclusion criteria
  • 1. Subject has no experience of using Study Drug.
  • 2. Subject is from 6 to under 18 years old (as of starting Study Drug administration). (The investigation will be continued when the subjects become over the age of 18 during the observation period.)
  • 3. Subject has no experience of using other AD/HD drugs for 14 days before starting Study Drug administration (except the date of starting Study Drug administration).
  • 4. Subject has the teacher's and physician's evaluation score by the ADHD RS-IV before starting Study Drug administration.

排除标准

  • 未提供

研究者

相似试验

进行中(未招募)
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中(未招募)
1 期
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placebo
EUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
进行中(未招募)
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861
EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
进行中(未招募)
不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078
EUCTR2005-006029-94-BEEisai Limited720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943
NL-OMON30044Janssen-Cilag82